Eribis Pharmaceuticals Receives Investment for Clinical Development of Novel Cardiovascular Therapy
In studies to date, Eribis' novel peptide therapy has shown excellentCardio-protective effects in conditions of ACS and reperfusion. Potentialbenefits of the candidate drug include a decrease in the amount of cardiactissue damage, an extension of the window of time available for treatment ofischemic conditions and a reduction of cardiovascular complications such asheart failure.
Eribis Pharmaceutical's CEO, Herman Krapf, said, "We are delighted thatKarolinska Development continues to show confidence in our developmentprogram. This latest round of financing comes after strong preclinicalresults and means we can now move forward towards the clinical program.Successful development offers significant market potential as there is anurgent need for new and improved therapies in the area of cardio-protection."
About Acute Coronary Syndrome
Cardiovascular disorders are the leading cause of mortality worldwide andremain an area of unmet medical needs. Acute coronary syndrome (ACS) refersto any group of clinical symptoms compatible with acute myocardial ischaemia(chest pain due to insufficient blood supply to the heart muscle that resultsfrom coronary artery disease). The consequence of an ACS event is destructionof the heart tissue due to reduced blood flow to the heart. Followingrecovery from an episode of ACS, patients continue to be at heightened riskof heart attack and stroke.
About Eribis Pharmaceuticals
Eribis Pharmaceuticals is focused on the development of novel drugs forthe treatment of cardiovascular disorders, in particular acute myocardialischemia, as well as surgical preconditioning. The company has uniquecompetence in the development of peptides for pharmacological use. Eribis'novel peptide candidate drug represents a new drug category aimed at meetingthe market need for new and improved treatment in the field ofcardio-protection.Eribis is a Karolinska Development AB portfolio company.
About Karolinska Development
Karolinska Development manages one of the largest portfolios of lifescience companies in Europe. Using a unique, highly cost-efficient businessmodel, the management team guides the commercialization of world-class lifescience innovations, helping to shape the next-generation pharma industry.Since 2003, Karolinska Development has built a portfolio of some 40companies; among the company's projects 12 compounds are undergoing clinicaltrials. The portfolio also includes a total of 19 potential first-in-classproducts.http://www.karolinskadevelopment.com For more information, please contact: Herman Krapf CEO Herman.email@example.com +46-70-666-50-95
SOURCE Eribis Pharmaceuticals AB
You May Also Like